Last reviewed · How we verify
NCT02534467
Does Treatment With Montelukast Improve Symptoms of Atopic Dermatitis in Children?
Phase 4 trial testing Montelukast in Dermatitis, Atopic in 60 participants. Completed in 4 December 2018.
4 December 2018
Quick facts
| Lead sponsor | Murdoch Childrens Research Institute |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 9 July 2015 |
| Primary completion | 4 December 2018 |
| Estimated completion | 4 December 2018 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Montelukast (montelukast) — full drug profile →
Conditions studied
- Dermatitis, Atopic — all drugs for Dermatitis, Atopic →
Sponsor
Murdoch Childrens Research Institute
Who can join
Adults 6 to 16, any sex, with Dermatitis, Atopic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An open-label (outcome assessor blinded) prospective crossover cohort study of children 6-16 years assessing effects of Montelukast on moderate to severe atopic dermatitis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02534467
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Montelukast
Trials testing the same drug.
- NCT07320625 — Efficacy of Montelukast on STEMl Patients · Phase 3 · recruiting
- NCT07101445 — Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injecti · Phase 4 · recruiting
- NCT06356571 — A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Partici · Phase 2 · recruiting
- NCT05922761 — BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) · Phase 2 · recruiting
- NCT05896228 — Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma · Phase 2 · recruiting
Other recruiting trials for Dermatitis, Atopic
Currently open trials in the same condition.
- NCT07230860 — A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
- NCT06899204 — Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate · recruiting
- NCT07042126 — Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
- NCT06881251 — A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) · Phase 2 · active not recruiting
- NCT06554847 — Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis · Phase 3 · active not recruiting
Other Murdoch Childrens Research Institute trials
Trials by the same sponsor.
- NCT07251790 — Optimising Breathing Support at Extubation in Very Preterm Infants: A Clinical Study · NA · not yet recruiting
- NCT07136584 — SOS for Caregiver Wellbeing · NA · recruiting
- NCT06686446 — Allergic Rhinitis Improvement Through Strategic Education: The ARISE Trial · NA · terminated
- NCT06992141 — A Strep Throat Controlled Human Infection Trial in Healthy Adults · EARLY_PHASE1 · completed
- NCT06186141 — Nausea and Vomiting in Postoperative Paediatric Patients With Patient-Controlled Analgesia (PCA): Morphine vs Oxycodone · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02534467 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Murdoch Childrens Research Institute
- Last refreshed: 22 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02534467.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing